May 8, 2017

Landmark clinical data highlight an advance in the management of Functional Dyspepsia (FD) with FDgard®, the only product available for the dietary management of FD. FDgard® demonstrated unprecedented symptom reduction and rapid relief of FD symptoms in patients in only 24 hours. This data was presented during Digestive Disease Week (DDW), a premier gastroenterology meeting.

Read More

May 23, 2016

IM HealthScience® (IMH), innovators of non- prescription IBgard® for the management of irritable bowel syndrome (IBS), announced today the planned retirement of Ellen Geisel...

Read More

October 17, 2016

(IMH) today announced interim results of FDACT™ (Functional Dyspepsia Adherence and Compliance Trial), a real-world observational study of 205 patients who took FDgard®...

Read More

April 3, 2017

IM HealthScience® (IMH) today announced favorable results from its Functional Dyspepsia Safety Update at 6 months (FDSU-6), a real-world, post-marketing surveillance study...

Read More